ZVRA Investors Have Opportunity to Join Zevra Therapeutics, Inc. Fraud Investigation with SBS LawSchall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zevra Therapeutics, Inc. (“Zevra” or “the Company”) (NASDAQ: ZVRA) for violations of the securities laws.INVESTIGATION DETAILS: The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. On July 24, 2026, Zevra received a negative opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use ("CHMP") on the Marketing Authorization Application for arimoclomol, branded Meplyffa. Based on this news, shares of Zevra fell sharply on the same day.If you are a shareholder who suffered a loss, click here to participate.We also encourage you to contact Brian Schall or David Schwartz of Schall, Brown & Schwartz LLP, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at david@schallfirm.comWHY SBS? Schall, Brown & Schwartz LLP represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. Bringing together the extensive experience and diverse skillsets of founding partners Brian Schall, Andrew Brown, and David Schwartz, SBS is dedicated to aggressively advocating for every investor.This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics. Schall, Brown & Schwartz LLPBrian Schall, Esq.Andrew Brown, Esq.David Schwartz, Esq.www.schallfirm.comOffice: 310-301-3335info@schallfirm.comView source version on businesswire.com: https://www.businesswire.com/news/home/20260727201341/en/
ZVRA Investors Have Opportunity to Join Zevra Therapeutics, Inc. Fraud Investigation with SBS Law
ZVRA Investors Have Opportunity to Join Zevra Therapeutics, Inc. Fraud Investigation with SBS LawSchall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zevra Therapeutics, Inc. (“Zevra” or “the Company”) (NASDAQ: ZVRA) for violations of the securities laws.INVESTIGATION DETAILS: The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. On July 24, 2026, Zevra received a negative opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use ("CHMP") on the Marketing Authorization Application for arimoclomol, branded Meplyffa. Based on this news, shares of Zevra fell sharply on the same day.If you are a shareholder who suffered a loss, click here to participate.We also encourage you to contact Brian Schall or David Schwartz of Schall, Brown & Schwartz LLP, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at david@schallfirm.comWHY SBS? Schall, Brown & Schwartz LLP represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. Bringing together the extensive experience and diverse skillsets of founding partners Brian Schall, Andrew Brown, and David Schwartz, SBS is dedicated to aggressively advocating for every investor.This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics. Schall, Brown & Schwartz LLPBrian Schall, Esq.Andrew Brown, Esq.David Schwartz, Esq.www.schallfirm.comOffice: 310-301-3335info@schallfirm.comView source version on businesswire.com: https://www.businesswire.com/news/home/20260727201341/en/
Zevra Therapeutics received a negative EMA opinion for arimoclomol on July 24, causing ZVRA stock to fall sharply; litigation is probing alleged fraud in investor disclosures. Regulatory failures in biotech represent material risk to value creation—critical consideration for tech leaders in healthcare-AI partnerships, due diligence, and compliance governance.
